Aclaris Therapeutics, Inc. (ACRS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1237401,
    "name": "Aclaris Therapeutics, Inc.",
    "stock_name": "Aclaris Therapeutics, Inc.",
    "full_name": "Aclaris Therapeutics, Inc.",
    "name_url": "stocks-analysis/aclaris-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.92",
    "chg": -0.09,
    "chgp": "-2.99%",
    "dir": -1,
    "prev_price": "3.01",
    "mcapval": "225.33",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US00461U1051",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.67 M",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aclaris-therapeutics-inc-1237401-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Aclaris Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aclaris-therapeutics-forms-golden-cross-signaling-potential-bullish-breakout-3595294",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AclarisTherapeu_goldencross_3595294.png",
        "date": "2025-10-06 15:30:39",
        "description": "Aclaris Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock shows a bullish trend in daily moving averages, despite recent volatility. Over the past year, it has outperformed the S&P 500, suggesting a possible positive shift in investor sentiment."
      },
      {
        "title": "Is Aclaris Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aclaris-therapeutics-inc-technically-bullish-or-bearish-3546637",
        "imagepath": "",
        "date": "2025-09-20 19:37:27",
        "description": "As of 8 August 2025, the technical trend for Aclaris Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and Bollinger Bands are mildly bullish. However, the daily moving averages and OBV are mildly bearish, indicating some mixed signals. The stock has shown a 1-month return of 5.41%, outperforming the S&P 500's 2.33% return, but it has underperformed significantly on a year-to-date basis with a return of -21.37% compared to the S&P 500's 12.22%. Overall, the current stance is mildly bullish, supported by the positive momentum in the weekly indicators...."
      },
      {
        "title": "Is Aclaris Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aclaris-therapeutics-inc-overvalued-or-undervalued-3543169",
        "imagepath": "",
        "date": "2025-09-20 18:12:35",
        "description": "As of 12 March 2018, the valuation grade for Aclaris Therapeutics, Inc. moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.15, an EV to Sales ratio of 3.42, and an EV to Capital Employed of 1.55. \n\nIn comparison to peers, Aclaris has a P/E ratio of -4.8751, while Evolus, Inc. has a P/E of -8.2365, indicating that Aclaris is less attractive in terms of valuation among its peers. The negative returns of Aclaris reinforce its overvaluation stance, especially when considering the lack of positive returns compared to the S&P 500...."
      }
    ],
    "total": 8,
    "sid": "1237401",
    "stock_news_url": "https://www.marketsmojo.com/news/aclaris-therapeutics-inc-1237401"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Aclaris Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-06 15:30:39

Aclaris Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock shows a bullish trend in daily moving averages, despite recent volatility. Over the past year, it has outperformed the S&P 500, suggesting a possible positive shift in investor sentiment.

Is Aclaris Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:37:27

As of 8 August 2025, the technical trend for Aclaris Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and Bollinger Bands are mildly bullish. However, the daily moving averages and OBV are mildly bearish, indicating some mixed signals. The stock has shown a 1-month return of 5.41%, outperforming the S&P 500's 2.33% return, but it has underperformed significantly on a year-to-date basis with a return of -21.37% compared to the S&P 500's 12.22%. Overall, the current stance is mildly bullish, supported by the positive momentum in the weekly indicators....

Is Aclaris Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:12:35

As of 12 March 2018, the valuation grade for Aclaris Therapeutics, Inc. moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.15, an EV to Sales ratio of 3.42, and an EV to Capital Employed of 1.55. In comparison to peers, Aclaris has a P/E ratio of -4.8751, while Evolus, Inc. has a P/E of -8.2365, indicating that Aclaris is less attractive in terms of valuation among its peers. The negative returns of Aclaris reinforce its overvaluation stance, especially when considering the lack of positive returns compared to the S&P 500....

View All News